AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?

Source The Motley Fool

Key Points

  • AbbVie generates significant cash flow from its newer immunology stars, Skyrizi and Rinvoq.

  • Eli Lilly is seeing explosive revenue growth driven by its dominant presence in the metabolic health market.

  • Which pharmaceutical giant offers the best balance of growth and value for your 2027 portfolio?

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

As the weight-loss drug craze and the recovery from patent cliffs redefine the medical landscape, investors are closely watching AbbVie Inc. (NYSE:ABBV) and Eli Lilly & Co. (NYSE:LLY) to see which giant will lead in the next decade.

AbbVie is focused on diversifying its immunology and aesthetics portfolios to replace legacy revenue, while Eli Lilly is scaling production for its massive metabolic health blockbusters. Comparing these two reveals a choice between a high-growth momentum play and a diversified, cash-rich value opportunity.

The case for AbbVie

AbbVie focuses on discovering and marketing advanced therapies for complex conditions, particularly in immunology, oncology, and aesthetics. The company relies heavily on wholesale distributors like McKesson Corp. (NYSE:MCK), Cardinal Health Inc. (NYSE:CAH), and Cencora Corp. (NYSE:COR) for its pharmaceutical stocks distribution. These distributors account for nearly all U.S. sales, and customer concentration like this adds a layer of risk to the business.

In the 12 months ended Sept. 30, 2026, revenue reached approximately $66.0 billion, which represents a revenue growth rate of about 10.7%. During this same period, the company reported net income of around $10.3 billion. This performance highlights the company's ability to grow its top line even as it navigates the loss of exclusivity for older products.

As of its December 2025 balance sheet, the debt-to-equity ratio was -13.1x, indicating that total liabilities exceeded shareholders' equity. Its current ratio stands at roughly 0.7x, which measures the company's ability to pay short-term obligations with assets that can be converted to cash quickly. In the fiscal year ended Dec. 31, 2025, free cash flow was approximately $17.8 billion, representing cash from operations minus capital expenditures.

The case for Eli Lilly & Co.

Eli Lilly researches and manufactures medicines across several therapeutic areas, with a massive current focus on cardiometabolic products and oncology. The company sells its products through major distributors such as McKesson, Cencora, and Cardinal Health, while also using its LillyDirect platform to reach patients. These large wholesalers manage a significant portion of the company's volume, creating a concentrated customer base that requires careful management.

In the 12 months ended Sept. 30, 2026, revenue reached around $86.5 billion, indicating an impressive revenue growth rate of roughly 45.5%. Net income for this period was about $27.6 billion, showing significant profitability as its new medications gain market share. This rapid expansion is primarily fueled by high demand for its newest metabolic treatments.

As of its December 2025 balance sheet, the debt-to-equity ratio was approximately 3.24x, comparing total debt to shareholder equity. The current ratio was roughly 1.6x, providing a healthy cushion for meeting short-term financial commitments. In the fiscal year ended Dec. 31, 2025, free cash flow reached about $8.7 billion, which is the cash remaining after the company pays for its operating costs and capital investments.

Risk profile comparison

AbbVie faces significant revenue concentration, as two immunology drugs, Skyrizi and Rinvoq, accounted for roughly 42% of its 2025 revenue. The company is also vulnerable to the loss of patent protection, which can lead to rapid revenue declines when biosimilar competitors enter the market. Additionally, pricing pressures from government payers and high failure rates in clinical research create ongoing uncertainty for the long-term pipeline.

Eli Lilly carries risks related to its high concentration in cardiometabolic products, which made up roughly 56% of its 2025 revenue. The company operates in a fiercely competitive environment against rivals like GSK plc (NYSE:GSK), Incyte Corporation (NASDAQ:INCY), and Innovent Biologics (OTC:IVBXF). Furthermore, complex manufacturing requirements and potential supply chain disruptions could hinder its ability to meet the soaring global demand for its flagship products.

Valuation comparison

AbbVie appears to be the more conservatively priced option based on its Forward P/E and P/S ratio, which compares market value to sales over the past twelve months.

MetricAbbVieEli Lilly
Forward P/E20.2x38.1x
P/S ratio7.6x14.7x

Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

Which stock would I buy for 2027?

Eli Lilly & Co. is perhaps the fastest-growing large-cap pharmaceutical stock around, with a massive sales jump last year. Lilly is riding a wave of success with its GLP-1 drugs Zepbound for weight loss and Mounjaro for diabetes control. There is still plenty of growth left in the treatment, and that is expected to power revenue up more than a third in 2026, to $91.7 billion, with close to $31 billion in net income.

Its next weight-loss drug, Retatrutide, is hotly anticipated for its triple-agonist approach, which is expected to exceed the weight-loss results of Zepbound. The company is also targeting less affluent customers with a lower-cost GLP pill called Foundayo, which it sells directly to consumers.

Besides GLP-1s, Lilly is working on a small interfering RNA therapeutic targeting lipoprotein(a) for the prevention of atherosclerotic cardiovascular disease in patients with elevated lipoprotein(a) levels. Analysts believe it will be a blockbuster ($1 billion or more in lifetime revenue) if approved.

Lilly shares come at a premium, but that is buying into future growth.

Meanwhile, AbbVie is buying itself growth with its recent deal to acquire Apogee Therapeutics. Its two relatively new immunology products, Skyrizi and Rinvoq, have proven to be true growth drivers for the business, and investors are hopeful that the Food & Drug Administration's recent decision on the Parkinson's treatment Juvmo bodes well for the company. Sales for that treatment are expected to be gradual, especially until Medicare coverage is available, which isn't expected until 2028. It is expected to be a blockbuster eventually (meaning more than $1 billion in lifetime revenue). Closer in, AbbVie is expected to see net income grow from $4.2 billion to $14.6 billion this year. Sales should grow to $67.2 billion.

AbbVie has a drug pipeline that some on Wall Street believe could include additional blockbusters for treating schizophrenia, psychosis from Alzheimer's, and certain solid tumors.

The choice here is between two pharmaceutical companies firing on all cylinders right now. AbbVie and Eli Lilly are both good choices. The better value for 2027? AbbVie, given that its forward P/E ratio is 20.2 x compared top 38/1x for Lilly. That puts AbbVie's P/E just above the average S&P 500 stock--a good deal considering its growth prospects.

Should you buy stock in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $315,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $896,981!*

Now, it’s worth noting Stock Advisor’s total average return is 768% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 20, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Eli Lilly, and Incyte. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Spot Gold Breaches Four Key Levels, Putting $3,500 at Risk as Technicals Enter Oversold Alert Zone International gold prices extended their accelerating decline. On November 20, spot gold (XAUUSD) briefly dipped to around $3,514.6, having fallen for multiple consecutive trading days an
Author  TradingKey
6 hours ago
International gold prices extended their accelerating decline. On November 20, spot gold (XAUUSD) briefly dipped to around $3,514.6, having fallen for multiple consecutive trading days an
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 20, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
Author  Mitrade
13 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 20, 2026. Read on for the details.
placeholder
TradingKey Daily Market Brief: Three Major US Indexes Drop Over 2%, Anthropic Gains 17% on DebutTracking Market TrendsTradingKey - All three major U.S. stock indices fell more than 2%, with the Nasdaq Composite Index (IXIC) down 2.25% to 23,879.20 points; the Dow Jones Industrial Average (DJIA)
Author  TradingKey
15 hours ago
Tracking Market TrendsTradingKey - All three major U.S. stock indices fell more than 2%, with the Nasdaq Composite Index (IXIC) down 2.25% to 23,879.20 points; the Dow Jones Industrial Average (DJIA)
placeholder
Gold Price Forecast: XAU/USD regains ground below $3,700, outlook remains fragileGold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
Author  FXStreet
Yesterday 08: 46
Gold price (XAU/USD) attracts some bids after hitting a fresh yearly low at $3,693.50 on Thursday. In the European trade, the Gold price is 0.42% higher to near $3,740.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 19, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
Author  Mitrade
Yesterday 03: 34
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 19, 2026. Read on for the details.
goTop
quote